AIDX Provides Business Update Highlighting FDA Engagement and Q2 Commercial Progress

AIDX (20/20 Biolabs, Inc.) provided a business update via an investor presentation, detailing recent preliminary discussions with the FDA for its OneTest multi-cancer early detection (MCED) test and significant commercial momentum in Q2 2026.

Key Details

• FDA Engagement: On August 25-26, 2026, the company held preliminary, in-person discussions with senior FDA personnel regarding the regulatory pathway for its OneTest MCED product, focusing on evidence generation and strategic planning.
• Commercial Performance: Reported its best quarterly cancer testing revenue to date in Q2 2026, with a 47% year-over-year increase and 29 orders from new accounts.
• Program Expansion: The Maryland Firefighter Cancer Screening Program grew over 200% from 2025, with 1,400+ participants. The company was also selected for the Vermont Firefighter Cancer Screening Program, with up to 4,500 potential participants.
• M&A Strategy: The company outlined its M&A strategy to acquire or 'bolt-on' health and wellness companies with $2 to $8 million in annualized revenue to accelerate growth.